WASHINGTON: The number of coronavirus infection cases across the world has surged to 14,425,865and the pandemic has so far claimed over 604,917 lives.
According to the latest data, 8,612,194patients have recovered from the pandemic so far. The United States tops with nearly 3,833,271cases and more than 142,877 deaths followed by Brazil with over 2,075,246cases and more than 78,817deaths.
India has reported 1,077,864cases while 26,828deaths due to the COVID-19. Over 765,437people have infected while 12,247people died of the virus in Russia.
The country has the third-highest number of recorded infections in the world. Peru has reported 349,500cases while 12,998deaths. In Chile, nearly 328,846cases were confirmed, including 8,445 deaths.
Spain has recorded 28,420fatalities and 307,335 infections. Mexico has reported 38,888deaths and 338,913cases. The United Kingdom has reported 45,273 fatalities and 294,066infections.
Meanwhile, the death toll is 13,979in Iran as a confirmed number of cases are almost 271,606. Italy has 35,042 fatalities, while 244,216infections.
Germany has reported 9,162deaths and 202,572 infections. Turkey reported 218,717 coronavirus cases and 5,475 fatalities. France has reported 30,152 deaths and 174,674cases.
China has to date declared 4,634 deaths and 83,660 cases, with 78,775 recoveries. Azerbaijan reported 349 fatalities and 27,1331infections due to coronavirus.
Japan has reported 24,132 coronavirus cases while 985 deaths. Saudi Arabia has reported 248,416 cases of coronavirus, while 2,447 coronavirus deaths have been reported. Germany has reported 202,572 coronavirus cases while 9,162deaths.
Chinese vaccine developer CanSino Biologics is in talks with Russia, Brazil, Chile and Saudi Arabia to launch a Phase III trial of its experimental COVID-19 vaccine, its co-founder said on Saturday.
China’s success in driving down COVID-19 infections has made it harder to conduct large-scale vaccine trials, and so far only a few countries have agreed to work with it.
“We are contacting and Russia, Brazil, Chile and Saudi Arabia (for the Phase III trial) and it’s still in discussion,” Qiu Dongxu, executive director and co-founder of CanSino, told an anti-viral drug development conference in Suzhou, in eastern China.
He said its Phase III trials were likely to start “pretty soon,” and the company plans to recruit 40,000 participants for the tests.
ADVERTISEMENT
